ASCO: Vorasidenib Improves Progression-Free Survival in Grade 2 IDH-Mutant Glioma

TUESDAY, June 6, 2023 -- Vorasidenib significantly improves progression-free survival among patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, according to a study published online June 4 in the New England Journal of Medicine to...